SAN DIEGO, CA, April 07, 2022 (GLOBE NEWSWIRE) – via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States to launch the world’s first cannabis-derived products, brands and supply chain, is pleased to provide the company with an update on its pharmaceutical investments targeting new treatments for unmet medical needs in the Large and rare disease markets.
As a “first company”, Medical Marijuana, Inc. We are widely recognized as a market leader in nutritional supplements with our high-quality cannabidiol (CBD) products but we also want our supporters to know that we’ve been working hard to support our investments focused on innovation in the pharmaceutical industry,” said Medical Marijuana CEO Blake Schroeder. “Our overall goal is to bring wellness to people around the world and create tremendous value for our shareholders by focusing our efforts and investments on both the nutritional and pharmaceutical applications of hemp and its derivatives.”
Medical Marijuana, Inc.
For the past five years, Medical Marijuana, Inc. Hard to network and build meaningful relationships with medical professionals throughout Brazil and Mexico. In Brazil, CBD is currently allowed for medical use only with permission from the country’s National Health Surveillance Agency (Anvisa), and a doctor has only made a prescription once. The company lays the groundwork for the drug registration application in Brazil. Further updates to this initiative are expected in the latter part of this year and into next year.
Neuropathix Investment Program Gaining Momentum for Pain
Neuropathics (OTCQB: NPTX), a major investment of Medical Marijuana, Inc. and a life sciences company for socially responsible pain management, and focuses on treating neuropathic pain, a condition Approximately 16 million Americans suffer each year. Kannalife Sciences, Inc. , a wholly owned subsidiary of Neuropathix, Received a grant of $2.97 million from National Institutes of Health (NIH) HEAL مبادرة Initiative For studies enabling the IND and enhancing its clinical program for KLS-13019, its Worldwide patent, a compound derived from cannabis. KLS-13019 is a leading candidate drug for the treatment of neuropathic pain and a potential alternative to opioids.
Neuropathix continues to advance the preparation of an IND file for the use of KLS-13019 in chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 showed manuals in Preclinical animal studies for the prevention and reversal of chemotherapy-related neuropathic pain. The next two major steps in 2022 for Neuropathix will be the successful completion of the first phase of commercial expansion and study of drug differentiation in animals.
Investment company AXIM Biotechnologies makes significant progress in the diagnosis of dry eye diseases
AXIM Biotech (OTCQB: AXIM), another major investment by Medical Marijuana, Inc. and an international healthcare diagnostics company, recently made significant progress in its Dry Eye Disease (DED) diagnostic program. It is estimated that DED affects Approximately 6.8% of the US population.
AXIM has obtained two ophthalmic diagnostic laboratory tests that have already received FDA approval for use and commercial sale. These tests, designed to help eye care clinicians detect and measure a variety of biomarkers associated with external eye disorders, measure lactoferrin, a protein found in tears that protects the surface of the eye with its antimicrobial and anti-inflammatory properties, and immunoglobulin E (IgE), a key biomarker associated with Mainly with dry eye disease.
AXIM has also successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker of dry eye disease, for which the company will seek FDA approval. The test is the first of its kind as there are no other specific tear tests that measure levels of this biomarker in human patients.
In 2022, AXIM aims to conduct several field and clinical studies to test MMP-9 and bring Lactoferrin and IgE tests to market. After completing the required studies, AXIM intends to submit its application for testing to the FDA.
To learn more about Medical Marijuana, Inc. And to keep abreast of the achievements of its portfolio companies, please visit https://investors.medicalmarijuanainc.com/.
About Medical Marijuana, Inc.
We are Firsts® شركة. Medical Marijuana, Inc. (MJNA) is a cannabis company comprising three distinct business units in the non-psychoactive cannabis space: a global group of cannabis-based food brands led by Kannawi® And HempMeds®; A leader in sourcing high-quality, legal, non-psychoactive cannabis products derived from industrial hemp; and the sector of cannabis-based clinical research and development of plant-based medicines led by pharmaceutical investment firms and partners including AXIM® Biotechnologies, Inc. And Neuropathics. Medical Marijuana, Inc. As the best CBD product ever CNBC In 2019. It was Medical Marijuana, Inc. Also the first company to obtain historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a pioneer in developing international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in. in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To watch a video of Medical Marijuana, Inc. , click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor law created by those sections. This material contains statements about expected future events and/or financial results of a forward-looking nature and subject to risks and uncertainties. These forward-looking statements by definition include risks, uncertainties and other factors, which could cause Medical Marijuana, Inc.’s actual results, performance or achievements to differ. materially from the data contained herein.
Disclosure by the Food and Drug Administration (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not. Selling or distributing any products that violate the Controlled Substances Act in the United States.
Public Relations Contact:
Public Relations Account Manager
Investor Relations Contact:
p. (858) 283-4016